Quidel Co. (NASDAQ:QDEL) Director Mary Lake Ph D. Polan sold 16,002 shares of the company’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $70.03, for a total value of $1,120,620.06. Following the completion of the sale, the director now owns 29,653 shares in the company, valued at approximately $2,076,599.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of QDEL stock opened at $71.34 on Wednesday. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -1,019.14, a price-to-earnings-growth ratio of 1.10 and a beta of 0.93. The company has a current ratio of 1.10, a quick ratio of 0.71 and a debt-to-equity ratio of 0.22. Quidel Co. has a 12-month low of $32.23 and a 12-month high of $73.36.

Quidel (NASDAQ:QDEL) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.12. The company had revenue of $103.16 million for the quarter, compared to the consensus estimate of $102.15 million. Quidel had a return on equity of 19.39% and a net margin of 4.63%. research analysts predict that Quidel Co. will post 2.55 EPS for the current year.

Hedge funds have recently modified their holdings of the business. NewSquare Capital LLC purchased a new position in Quidel during the second quarter worth approximately $178,000. Mackay Shields LLC purchased a new position in Quidel during the first quarter worth approximately $202,000. Great West Life Assurance Co. Can boosted its position in Quidel by 55.8% during the second quarter. Great West Life Assurance Co. Can now owns 3,405 shares of the company’s stock worth $227,000 after purchasing an additional 1,220 shares in the last quarter. Winslow Evans & Crocker Inc. purchased a new position in Quidel during the second quarter worth approximately $236,000. Finally, Xact Kapitalforvaltning AB acquired a new position in shares of Quidel during the first quarter valued at approximately $241,000. Institutional investors own 88.46% of the company’s stock.

A number of analysts have recently commented on the company. BidaskClub downgraded Quidel from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 26th. Canaccord Genuity upped their target price on Quidel from $75.00 to $78.00 and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Piper Jaffray Companies restated an “overweight” rating and issued a $74.00 target price on shares of Quidel in a research note on Wednesday, August 8th. Barclays restated a “buy” rating and issued a $65.00 target price on shares of Quidel in a research note on Thursday, May 10th. Finally, TheStreet upgraded Quidel from a “c” rating to a “b” rating in a research report on Tuesday, May 8th. Eight analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $69.86.

About Quidel

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

Featured Article: What is a Fiduciary?

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.